Adynxx attracts $16 mln Series B
San Francisco-based Adynxx, which focuses on treating and preventing chronic pain, has raised $16 million in Series B financing. TPG Biotech led the round with participation from return backer Domain Associates. In conjunction with the financing, Dr. Heath Lukatch, a partner and managing director at TPG Biotech, has been added to Adynxx's board of directors.
10 January 2017•1 min read
